At the time of writing, Ginkgo Bioworks Holdings Inc [DNA] stock is trading at $11.32, up 11.75%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The DNA shares have gain 13.88% over the last week, with a monthly amount glided 31.93%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Ginkgo Bioworks Holdings Inc [NYSE: DNA] stock has seen the most recent analyst activity on May 15, 2024, when BTIG Research downgraded its rating to a Sell. Previously, William Blair downgraded its rating to Underperform on May 10, 2024. On November 14, 2023, downgrade downgraded it’s rating to Mkt Perform and revised its price target to $2.50 on the stock. BTIG Research downgraded its rating to a Neutral. Goldman downgraded its rating to a Sell and reduced its price target to $1.25 on June 02, 2023. William Blair downgraded its rating to Mkt Perform for this stock on May 11, 2023. In a note dated November 29, 2022, Berenberg initiated an Buy rating and provided a target price of $6 on this stock.
For the past year, the stock price of Ginkgo Bioworks Holdings Inc fluctuated between $5.00 and $16.85. Currently, Wall Street analysts expect the stock to reach $7.34 within the next 12 months. Ginkgo Bioworks Holdings Inc [NYSE: DNA] shares were valued at $11.32 at the most recent close of the market. An investor can expect a potential drop of -35.16% based on the average DNA price forecast.
Analyzing the DNA fundamentals
According to Ginkgo Bioworks Holdings Inc [NYSE:DNA], the company’s sales were 237.42M for trailing twelve months, which represents an 27.34% jump. Gross Profit Margin for this corporation currently stands at 0.74% with Operating Profit Margin at -1.98%, Pretax Profit Margin comes in at -1.99%, and Net Profit Margin reading is -1.99%. To continue investigating profitability, this company’s Return on Assets is posted at -0.36, Equity is -0.63 and Total Capital is -0.4. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.67.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It is important to note that Ginkgo Bioworks Holdings Inc [NYSE:DNA] has a current ratio of 4.88. Further, the Quick Ratio stands at 4.88, while the Cash Ratio is 2.7. Considering the valuation of this stock, the price to sales ratio is 2.79, the price to book ratio is 0.90.
Transactions by insiders
Recent insider trading involved Coen Steven P.,, that happened on Jul 17 ’25 when 1084.0 shares were sold. Officer, Dmytruk Mark E. completed a deal on Jul 17 ’25 to buy 640.0 shares. Meanwhile, Officer Che Austin bought 2200.0 shares on Jul 09 ’25.
